Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARCH CAPITAL GROUP LTD.ACGL · Entity 3120 | Director | May 04, 2023 | May 08, 2023 |
| NorthStar Asset Management Group Inc.NSAM · Entity 16244 | Director | December 30, 2016 | January 04, 2017 |
| Sarissa Capital Acquisition Corp.SRSA · Entity 145567 | Director | October 23, 2020 | October 27, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARCH CAPITAL GROUP LTD.
Report date May 04, 2023 · Filed May 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, $.0011 par value per shareSEC Table I · non-derivative | Direct | 54,056 |
Reported balance
After 2023-05-04 transaction · row 1
1 source rowRow 1 · 2023-05-04 · Grant · Acquired 1,714 · Balance 54,056 F1: Subject to the terms of the restricted share agreement, represents restricted shares that will vest on May 4, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the terms of the restricted share agreement, represents restricted shares that will vest on May 4, 2024.
NorthStar Asset Management Group Inc.
Report date December 30, 2016 · Filed January 04, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 104,811 |
Reported balance
After 2016-12-30 transaction · row 1
1 source rowRow 1 · 2016-12-30 · Grant · Acquired 8,043 · Balance 104,811 F1: These shares of common stock of NorthStar Asset Management Group Inc. (the "Company") were granted in connection with the reporting person's service on the Company's board of directors for 2016 pursuant to the Company's 2014 Omnibus Stock Incentive Plan, and are immediately vested. The amount of common stock was determined by dividing the fixed grant value of $120,000 by the closing price of the Company's common stock on the New York Stock Exchange on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of common stock of NorthStar Asset Management Group Inc. (the "Company") were granted in connection with the reporting person's service on the Company's board of directors for 2016 pursuant to the Company's 2014 Omnibus Stock Incentive Plan, and are immediately vested. The amount of common stock was determined by dividing the fixed grant value of $120,000 by the closing price of the Company's common stock on the New York Stock Exchange on the grant date.
Sarissa Capital Acquisition Corp.
Report date October 23, 2020 · Filed October 27, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| UnitsSEC Table I · non-derivative | Direct | 6,000 |
Reported balance
After 2020-10-23 transaction · row 1
1 source rowRow 1 · 2020-10-23 · Purchase · Acquired 6,000 · Balance 6,000 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Bioverativ Inc.
Report date March 08, 2018 · Filed March 08, 2018
Section 16 reporting ended · disclosed 2018-03-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-03-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-03-05 · Gift · Disposed 2,000 · Balance 3,056 Row 2 · 2018-03-08 · Disposition to issuer · Disposed 3,056 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-03-08 · Disposition to issuer · Disposed 5,455 · Balance 0 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F3: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $44.51 | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-03-08 · Disposition to issuer · Disposed 26,818 · Balance 0 F4: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock.
F3: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.
F4: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.
NORTHSTAR REALTY FINANCE CORP.
Report date January 10, 2017 · Filed January 12, 2017
Section 16 reporting ended · disclosed 2017-01-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 57,081 |
Reported balance
After 2016-12-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2016-12-20 · Gift · Disposed 9,732 · Balance 57,081 F2: Includes (i) 7,153 shares of Common Stock issued on January 10, 2017 in exchange for an equal number of LTIP Units of NorthStar Realty Finance Limited Partnership ("NRFLP"), when, as part of the NRF Reorganization, NRFLP merged with a wholly owned subsidiary of NRF, resulting in all outstanding LTIP Units in NRFLP becoming fully vested and converting into an equal number of shares of Common Stock and (ii) shares of Common Stock acquired pursuant to NRF's distribution reinvestment plan. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-01-10 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2017-01-10 · Disposition to issuer · Disposed 64,234 · Balance 0 F1: On January 10, 2017, New Sirius Inc. ("New NRF") merged (the "CLNS Merger") with Colony NorthStar, Inc. ("CLNS"), which followed substantially concurrent reorganization transactions (the "NRF Reorganization") involving NorthStar Realty Finance Corp. ("NRF") pursuant to which NRF became a wholly owned subsidiary of New NRF, which had previously been a wholly owned subsidiary of NRF, and all of the outstanding shares of common stock, par value $0.01 per share, of NRF ("Common Stock") were converted into an equal number of shares of common stock of New NRF. F3: Disposed of pursuant to the merger of New NRF with and into CLNS in exchange for shares of CLNS common stock at a ratio of one share of New NRF common stock for 1.0996 shares of CLNS common stock having a market value of $15.84 per share on the effective date of the CLNS Merger based on the reported closing sale price on such date. Prior to the merger of New NRF with and into CLNS, all outstanding shares of Common Stock were automatically converted into an equal number of shares of New NRF common stock pursuant to the NRF Reorganization. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 10, 2017, New Sirius Inc. ("New NRF") merged (the "CLNS Merger") with Colony NorthStar, Inc. ("CLNS"), which followed substantially concurrent reorganization transactions (the "NRF Reorganization") involving NorthStar Realty Finance Corp. ("NRF") pursuant to which NRF became a wholly owned subsidiary of New NRF, which had previously been a wholly owned subsidiary of NRF, and all of the outstanding shares of common stock, par value $0.01 per share, of NRF ("Common Stock") were converted into an equal number of shares of common stock of New NRF.
F2: Includes (i) 7,153 shares of Common Stock issued on January 10, 2017 in exchange for an equal number of LTIP Units of NorthStar Realty Finance Limited Partnership ("NRFLP"), when, as part of the NRF Reorganization, NRFLP merged with a wholly owned subsidiary of NRF, resulting in all outstanding LTIP Units in NRFLP becoming fully vested and converting into an equal number of shares of Common Stock and (ii) shares of Common Stock acquired pursuant to NRF's distribution reinvestment plan.
F3: Disposed of pursuant to the merger of New NRF with and into CLNS in exchange for shares of CLNS common stock at a ratio of one share of New NRF common stock for 1.0996 shares of CLNS common stock having a market value of $15.84 per share on the effective date of the CLNS Merger based on the reported closing sale price on such date. Prior to the merger of New NRF with and into CLNS, all outstanding shares of Common Stock were automatically converted into an equal number of shares of New NRF common stock pursuant to the NRF Reorganization.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2023 Filed May 8, 2023 22:41 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0011 par value per share | 1,714 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-007588 · form4-05082023_100516.xml · nonDerivative · entry 1 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,056 F1 · price: Subject to the terms of the restricted share agreement, represents restricted shares that will vest on May 4, 2024. Read SEC document |
| May 04, 2022 Filed May 6, 2022 19:47 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0011 par value per share | 2,642 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-22-002871 · edgar.xml · nonDerivative · entry 1 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,342 F1 · price: Subject to the terms of the restricted share agreement, represents restricted shares that will vest on May 4, 2023. Read SEC document |
| May 06, 2021 Filed May 10, 2021 23:31 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0011 par value per share | 3,143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-21-005116 · edgar.xml · nonDerivative · entry 1 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,700 F1 · price: Subject to the terms of the restricted share agreement, represents restricted shares that will vest on May 1, 2022. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 19:36 UTC | Sarissa Capital Acquisition Corp. SRSA · Entity 145567 | PurchaseUnits | 6,000 | $10.25 | $61,500.00 |
DisclosureSEC source: 0000899243-20-029351 · doc4.xml · nonDerivative · entry 1 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Read SEC document |
| May 07, 2020 Filed May 11, 2020 13:15 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0011 par value per share | 5,058 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-005673 · edgar.xml · nonDerivative · entry 2 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,557 F2 · price: Subject to the terms of the restricted share agreement, represents restricted shares that will vest on May 1, 2021. Read SEC document |
| May 07, 2020 Filed May 11, 2020 13:15 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0011 par value per share | 5,058 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-005673 · edgar.xml · nonDerivative · entry 1 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,499 F1 · price: Represents shares granted as part of the director elected annual retainer for serving as a director of the Issuer. Read SEC document |
| May 08, 2019 Filed May 9, 2019 19:55 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0011 par value per share | 2,832 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-005754 · edgar.xml · nonDerivative · entry 2 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,441 F2 · price: Subject to the terms of the restricted share agreement, represents restricted shares that will vest on May 1, 2020. Read SEC document |
| May 08, 2019 Filed May 9, 2019 19:55 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0011 par value per share | 3,726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-005754 · edgar.xml · nonDerivative · entry 1 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,609 F1 · price: Represents shares granted as part of the director elected annual retainer for serving as a director of the Issuer. Read SEC document |
| May 09, 2018 Filed May 11, 2018 20:38 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0033 par value per share | 1,196 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-006652 · edgar.xml · nonDerivative · entry 2 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,961 F2 · price: Subject to the terms of the restricted share agreement, represents restricted shares that will vest on May 1, 2019. Read SEC document |
| May 09, 2018 Filed May 11, 2018 20:38 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0033 par value per share | 1,574 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-006652 · edgar.xml · nonDerivative · entry 1 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,765 F1 · price: Represents shares granted as part of the director elected annual retainer for serving as a director of the Issuer. Read SEC document |
| March 08, 2018 Filed Mar 8, 2018 12:44 UTC | Bioverativ Inc. BIVV · Entity 168487 | Disposition to issuerNon-Qualified Stock Option · Derivative | 26,818 | Not disclosed Strike: $44.51 | Not disclosed |
DisclosureSEC source: 0001127602-18-010671 · form4.xml · derivative · entry 4 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,818 shares Expires not disclosed F4 · shares: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F4 · price: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. Read SEC document |
| March 08, 2018 Filed Mar 8, 2018 12:44 UTC | Bioverativ Inc. BIVV · Entity 168487 | Disposition to issuerRestricted Stock Units · Derivative | 5,455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-010671 · form4.xml · derivative · entry 3 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,455 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F3 · shares: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F3 · price: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. Read SEC document |
| March 08, 2018 Filed Mar 8, 2018 12:44 UTC | Bioverativ Inc. BIVV · Entity 168487 | Disposition to issuerCommon Stock | 3,056 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-010671 · form4.xml · nonDerivative · entry 2 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash. Read SEC document |
| March 05, 2018 Filed Mar 8, 2018 12:44 UTC | Bioverativ Inc. BIVV · Entity 168487 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-010671 · form4.xml · nonDerivative · entry 1 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,056 Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 17:00 UTC | Bioverativ Inc. BIVV · Entity 168487 | GrantRestricted Stock Units · Derivative | 5,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-003790 · form4.xml · derivative · entry 1 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,455 Underlying: Common Stock · 5,455 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on the first anniversary of the date of grant. F2 · derivative.expiration_date: The restricted stock units vest in full on the first anniversary of the date of grant. Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 16:53 UTC | Bioverativ Inc. BIVV · Entity 168487 | PurchaseCommon Stock | 2,000 | $59.70 | $119,400.00 |
DisclosureSEC source: 0001127602-17-025251 · form4.xml · nonDerivative · entry 1 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,056 Read SEC document |
| May 26, 2017 Filed May 26, 2017 16:02 UTC | Bioverativ Inc. BIVV · Entity 168487 | PurchaseCommon Stock | 2,000 | $57.76 | $115,520.00 |
DisclosureSEC source: 0001127602-17-019557 · form4.xml · nonDerivative · entry 1 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,056 Read SEC document |
| May 04, 2017 Filed May 8, 2017 17:25 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0033 par value per share | 771 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-006785 · edgar.xml · nonDerivative · entry 2 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,191 F2 · price: Subject to the terms of the restricted share agreement, represents restricted shares that will vest on May 1, 2018. Read SEC document |
| May 04, 2017 Filed May 8, 2017 17:25 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0033 par value per share | 1,286 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-006785 · edgar.xml · nonDerivative · entry 1 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,420 F1 · price: Represents shares granted as part of the director elected annual retainer for serving as a director of the Issuer. Read SEC document |
| April 17, 2017 Filed Apr 17, 2017 16:12 UTC | Bioverativ Inc. BIVV · Entity 168487 | GrantCommon Stock | 1,056 | $56.83 | $60,012.48 |
DisclosureSEC source: 0001127602-17-014848 · form4.xml · nonDerivative · entry 1 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,056 F1 · shares: The common stock was issued to the reporting person pursuant to the 2017 Non-Employee Directors Plan in lieu of an annual retainer fee of $60,000. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 16:43 UTC | Bioverativ Inc. BIVV · Entity 168487 | GrantNon-Qualified Stock Option · Derivative | 26,770 | $0.00 Strike: $44.51 | $0.00 |
DisclosureSEC source: 0001127602-17-006627 · form4.xml · derivative · entry 1 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,770 Underlying: Common Stock · 26,770 shares Expires 2027-02-14 F1 · derivative.exercise_date: This option vests in three equal annual installments beginning on February 14, 2018. Read SEC document |
| February 14, 2017 Filed Mar 27, 2017 16:19 UTC Amendment | Bioverativ Inc. BIVV · Entity 168487 | GrantNon-Qualified Stock Option · Derivative | 26,818 | $0.00 Strike: $44.51 | $0.00 |
DisclosureSEC source: 0001127602-17-012940 · form4a.xml · derivative · entry 1 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,818 Underlying: Common Stock · 26,818 shares Expires 2027-02-14 F1 · shares: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing. F2 · derivative.exercise_date: This option vests in three equal annual installments beginning on February 14, 2018. F1 · derivative.underlying_shares: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing. F1 · balance_after: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing. Read SEC document |
| January 10, 2017 Filed Jan 12, 2017 21:44 UTC | NORTHSTAR REALTY FINANCE CORP. NRF · Entity 178832 | Disposition to issuerCommon Stock | 64,234 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001571049-17-000363 · t1700104x8.xml · nonDerivative · entry 2 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: On January 10, 2017, New Sirius Inc. ("New NRF") merged (the "CLNS Merger") with Colony NorthStar, Inc. ("CLNS"), which followed substantially concurrent reorganization transactions (the "NRF Reorganization") involving NorthStar Realty Finance Corp. ("NRF") pursuant to which NRF became a wholly owned subsidiary of New NRF, which had previously been a wholly owned subsidiary of NRF, and all of the outstanding shares of common stock, par value $0.01 per share, of NRF ("Common Stock") were converted into an equal number of shares of common stock of New NRF. F3 · price: Disposed of pursuant to the merger of New NRF with and into CLNS in exchange for shares of CLNS common stock at a ratio of one share of New NRF common stock for 1.0996 shares of CLNS common stock having a market value of $15.84 per share on the effective date of the CLNS Merger based on the reported closing sale price on such date. Prior to the merger of New NRF with and into CLNS, all outstanding shares of Common Stock were automatically converted into an equal number of shares of New NRF common stock pursuant to the NRF Reorganization. Read SEC document |
| December 30, 2016 Filed Jan 4, 2017 19:18 UTC | NorthStar Asset Management Group Inc. NSAM · Entity 16244 | GrantCommon Stock | 8,043 | $0.00 | $0.00 |
DisclosureSEC source: 0001571049-17-000142 · t1700010_x6.xml · nonDerivative · entry 1 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,811 F1 · price: These shares of common stock of NorthStar Asset Management Group Inc. (the "Company") were granted in connection with the reporting person's service on the Company's board of directors for 2016 pursuant to the Company's 2014 Omnibus Stock Incentive Plan, and are immediately vested. The amount of common stock was determined by dividing the fixed grant value of $120,000 by the closing price of the Company's common stock on the New York Stock Exchange on the grant date. Read SEC document |
| December 20, 2016 Filed Jan 12, 2017 21:44 UTC | NORTHSTAR REALTY FINANCE CORP. NRF · Entity 178832 | GiftCommon Stock | 9,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001571049-17-000363 · t1700104x8.xml · nonDerivative · entry 1 PAGLIA LOUIS J · CIK 0001199584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,081 F2 · balance_after: Includes (i) 7,153 shares of Common Stock issued on January 10, 2017 in exchange for an equal number of LTIP Units of NorthStar Realty Finance Limited Partnership ("NRFLP"), when, as part of the NRF Reorganization, NRFLP merged with a wholly owned subsidiary of NRF, resulting in all outstanding LTIP Units in NRFLP becoming fully vested and converting into an equal number of shares of Common Stock and (ii) shares of Common Stock acquired pursuant to NRF's distribution reinvestment plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.